Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enterprise Products Partners

Mastercard

NextEra Energy

PennantPark Floating Rate Capital

Although the S&P 500 and Nasdaq Composite have bounced back in a big way in 2023, there's no guarantee the upward momentum has legs. Five rock-solid companies with well-defined competitive advantages stand out as exceptionally smart and safe buys for the second half of the year.

5 Genius Safe Stocks to Buy for the Second Half of 2023

Johnson & Johnson is strategically shifting towards high-growth sectors like pharmaceuticals and medical devices. Technical analysis of JNJ's stock price shows a strong bullish trend, indicating the potential for further growth. A robust bounce-back from the 50-month moving average affirms the investment potential for long-term shareholders.

Johnson & Johnson: Buy The Market (Technical Analysis)

Johnson & Johnson is a top-tier Sleep-Well-At-Night (SWAN) stock due to its consistent growth, strong cash flow, and regular returns to shareholders. The company's profile is strong, but its dividend yield is weak. We propose a trade that stands to generate far more income from this underlying company, for those whose top objectives are income and principal protection.

Johnson & Johnson: Pay Yourself 7% With This Bond-Like Exposure

Despite a top-shelf dividend and an elite innovation engine, J&J stock has lagged the broader markets since 2017. With a strong near-term outlook, J&J ought to deliver better results for shareholders in the years ahead.

Is Johnson & Johnson Stock a Strong Buy?

Johnson & Johnson's sales growth has not been impressive in recent years. If it can resolve its talc lawsuits, perhaps J&J can pursue more acquisitions.

Where Will Johnson & Johnson Be in 5 Years?

AbbVie

Amgen

Bristol-Myers

Pfizer

Some of the biggest names in healthcare are on sale right now. J&J, AbbVie, Bristol Myers, Amgen, and Pfizer all trade at low valuations.

5 High-Yielding Dividend Stocks That Are Bargain Buys

Disney

Walgreens

The Dow Jones Industrial Average has not exactly been keeping up with the other indices so far this year. That fact has left behind a number of undervalued Dow stocks for value investing.

The 3 Most Undervalued Dow Stocks to Buy Now: June 2023

Federal Realty Investment Trust

Lowe's

As my readers know, I'm no market timer, I'm a value investor. Regardless of what Fed Chair Jerome Powell is telling us, I'm confident that the rate-hike cycle is going to end (sooner rather than later). When that happens (rates pause indefinitely), dividends should compress (go lower) and shares should move back to normal valuation levels.

Retire Rich With 'Dividend King' Royalty

Amazon

Merck

The VIX is showing that investors are feeling increasingly optimistic. This follows the S&P 500's 20% gain from its bear market low.

This Sentiment Gauge Just Reached Its Most Optimistic Level Since Pre-Covid Days. Time to Buy Stocks?

The lead negotiators for Johnson & Johnson's proposed $8.9 billion settlement of thousands of talc lawsuits faced intense questioning in U.S. bankruptcy court on Wednesday about how much support the company has for the deal.

Cancer plaintiffs drill down on J&J's support for $8.9 bln talc deal

Community Healthcare Trust

Medical Properties Trust

Medical Properties Trust's issues could force it to cut its big-time dividend. Johnson & Johnson backs its attractive dividend with an elite financial profile.

1 Sickly Dividend Stock to Avoid Like the Plague Right Now (and 2 Much Healthier Ones to Buy Instead)

Johnson & Johnson's proposed $8.9 billion settlement of thousands of lawsuits alleging that its talc products cause cancer faces a crucial hurdle this week as a U.S. bankruptcy judge in New Jersey considers whether or not a J&J subsidiary may resolve them by filing for bankruptcy a second time.

J&J's $8.9 billion talc settlement faces US bankruptcy test

A California man suing Johnson & Johnson told jurors on Monday how his life was upended by a cancer diagnosis that he blames on using the company's baby powder since childhood, as the first trial over the product in nearly two years neared its end.

California man tells jury of getting cancer after using J&J baby powder

McKesson

McKesson is the largest pharmaceutical distributor in the U.S. Johnson & Johnson is one of the largest healthcare companies in the world. Both stocks have steadily increased their dividends over the years.

2 Best Buffett Stocks to Buy for the Long Haul

Coca-Cola

Coca-Cola currently offers a 3% dividend yield. Johnson & Johnson pays a very healthy dividend.

Got $500? 3 Magnificent Dividend Stocks to Buy Without Hesitation Right Now

Apple

Adobe

Allianz SE

BB Seguridade Participacoes SA

Blackrock Inc

Bank of Nova Scotia

Canadian Natural Resources

Salesforce

iShares Core Dividend Growth ETF

Alphabet

Goldman Sachs

JPMorgan Chase & Co

Kinder Morgan

Altria

Microsoft

Nasdaq

Palo Alto Networks

PayPal

Schwab US Dividend Equity ETF

Charles Schwab

A dividend income-oriented investment portfolio can provide you with an excellent source of extra income via dividend payments. I will show you how you could build an investment portfolio with my top 10 high dividend yield, dividend growth, and growth companies for the month of June. This portfolio provides you with a Weighted Average Dividend Yield [TTM] of 3.58% and has shown a Weighted Average Dividend Growth Rate [CAGR] of 11.05%.

How To Build A Dividend Portfolio With $25,000 Among June's Top 30 Stocks

Ally Financial

CVS Health

Over time, dividend-paying stocks tend to deliver better returns than non-dividend payers. CVS Health and Johnson & Johnson are healthcare conglomerates that dividend investors appreciate for different reasons.

3 Reliable Dividend Stocks to Buy Now and Hold Forever

Boeing

The Dow Jones Industrial Average closed down 0.01%, or 4 points, spending most of the day in the red as investors digested the latest moves by central banks around the world.

Dow Jones Today: Index Flat as Investors Mull Global Rate Decisions

The global pharmaceutical industry keeps growing. J&J looks positioned to deliver growth for the long haul.

News for Johnson & Johnson Stock (JNJ)